Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients
A Randomized, Double-blind, Placebo-controlled, Parallel Group Trial Assessing the Rate of Decline of Lung Function With Tiotropium 18 mcg Inhalation Capsule Once Daily in Patients With Chronic Obstructive Pulmonary Disease (COPD).
Sponsor: Boehringer Ingelheim
This PHASE3 trial investigates Pulmonary Disease, Chronic Obstructive and is currently completed. Boehringer Ingelheim leads this study, which shows 8 recorded versions since 2002 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Change History
8 versions recorded-
Nov 2025 — Present [monthly]
Completed PHASE3
-
Sep 2025 — Nov 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE3
▶ Show 3 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Dec 2002
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Boehringer Ingelheim
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain, Aalborg, Denmark, Aalborg SV, Denmark, Aarhus, Denmark, Aberdeen, United Kingdom, Adana, Turkey (Türkiye), Albany, United States, Albi, France, Alessandria, Italy, Alicante, Spain and 383 more location s